Pioneering cancer research and drug development
The Sir Bobby Robson Cancer Trials Research Centre has pioneered life-extending cancer treatments like Rubraca™, now helping thousands worldwide. The Centre has had a role in other breakthrough cancer treatments including Erdafitinib for bladder cancer, Pemetrexed for mesothelioma and lung cancer, and Osimertinib for EGFR-mutated lung cancer. Early phase work on Dostarlimab for rare womb cancer, Olaparib for BRCA-related cancers, Tremilimumab for liver cancer, Sonidegib for basal cell carcinoma, and Tisotumab Vedotin for cervical cancer has led to global treatment advancements.
The ground-breaking Target National study, funded by the Sir Bobby Robson Foundation and The Christie Charity in Manchester, uses blood tests to match cancer patients to the best clinical trials and treatments with the potential to be life-changing if successful. Newcastle is the leading recruiter onto this trial with over 600 patients participating to date.
The Sir Bobby Robson Cancer Trials Research Centre
-
1 of 0
UK experimental Cancer Medicine Centres
-
0
m
people in our catchment
-
0
+
patients per year
-
1 of 0
Cancer Research UK Centres
CONCORDE study – innovation and impact in action
The CONCORDE study is a novel radiotherapy/drug combination study led-nationally by the Centre’s Professor Alastair Greystoke, funded by CRUK and individual arms of the study by pharma partners to enable collaboration. Dr Greystoke was a lead author with Professor Ruth Plummer as co-author and chair of the group who wrote an international guidance paper on trial design in response to the FDA’s Project Optimus. The guidance is widely quoted and used in trial design teaching.